| Paris | |
| 72 | |
| Biotech company that designs and develops cancer immunotherapy treatments using its Memopi® technology, through neo-epitopes (small synthetic peptides chemically modified to increase the binding the HLA A2 or TCR receptors) which triggers a cytotoxic T-cell response and leads the immune system to destroy cancer cells. | |
| Its lead product Tedopi® (OSE-2101) combines 10 optimized neo-epitopes simultaneously acting against 5 tumor-associated antigens (TAAs). These 5 antigens have been selected because they are a factor of poor prognosis in several types of cancers. The 10 optimized neo-epitopes have been selected and modified to enhance their binding to HLA-A2 and TCR receptors, and trigger a stronger T-cell response. These strong cytotoxic T-cell responses lead the immune system to destroy tumor cells expressing HLA-A2 antigens and one of the targeted tumor antigens (TCR). Based on promising Phase 2 results demonstrating a long survival of patients (considering how advanced their pathology was), a pivotal Phase 3 trial is initiated in patients diagnosed with stage IIIB (advanced) or IV (metastatic) non-small cell lung cancer (NSCLC) after at least one first line therapy failure. All patients express HLA-A2 receptor (representing 45% of NSCLC patients), which is a key receptor for the cytotoxic T-immune response and represents the responder Tedopi® population. Tedopi® is compared to current standard chemotherapy (docetaxel or pemetrexed, both approved in second therapy line). The primary endpoint of this trial is overall survival. It will include 500 patients in Europe and the United States, and is expected to be completed in 2018 provided that the recruitment of patients, their observed survival and the safety of the product meet the usual criteria for this kind of trials. |
|
| PEYROLES Alexis | |
| www.osepharma.com | |
| OSE:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 5 fois.